AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11237499
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) cisplatinum (CDP) in three-drug regimen
Trial: 11237499
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen (HDMTX, ADM, IFO) with i.a. CDP
Trial: 11237499
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen (HDMTX, ADM, IFO) with i.v. CDP
Trial: 8292844
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone
Trial: 8292844
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone releasing hormone
Trial: 22112743
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day)
Trial: 18262192
Drug: 2g LUVs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g LUVs infusion
Trial: 18262192
Drug: 8g LUVs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8g LUVs infusion
Trial: 18262192
Drug: Combined 2g
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 2g and 8g LUVs infusion
Trial: 15681956
Drug: Ropivacaine, 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine, 0.2% administered at 5 ml/h through the IC catheter for 48 hours
Trial: 15681956
Drug: Placebo (NaCl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl, 0.9%) administered at 5 ml/h through the IC catheter for 48 hours
Trial: 14597107
Drug: Pentamidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine treatment
Trial: 10550734
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 120 mg once daily
Trial: 10550734
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 180 mg once daily
Trial: 10550734
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg once daily (active control)
Trial: 8810686
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with cyclosporin (CyA) and methotrexate, mean final dose of 2.97 mg/kg per day CyA
Trial: 1921733
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + 50 mg micronized progesterone
Trial: 1921733
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + 100 mg micronized progesterone
Trial: 1921733
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + 200 mg micronized progesterone
Trial: 1921733
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + micronized progesterone (various doses)
Trial: 7048451
Drug: yohimbine chlorhydrate
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yohimbine chlorhydrate (4 mg)
Trial: 7048451
Drug: propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (40 mg)
Trial: 25892647
Drug: Bicalutamide 150mg
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150mg once daily
Trial: 15823766
Drug: Cefdinir 600
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 600 mg once daily for 10 days
Trial: 15823766
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once daily for 10 days
Trial: 2692973
Drug: Flupenthixol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol (0.5 mg tablet in the morning, placebo at night)
Trial: 2692973
Drug: Sustained-release amitriptyline
RxNorm normalized name: amitriptyline Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release amitriptyline (25 mg capsule at night, placebo in the morning)
Trial: 30782000
Drug: Triamcinolone hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide (TH) 40 mg
Trial: 30782000
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (SS) 0.9%
Trial: 29049653
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 2.5 mg
Trial: 29049653
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 5 mg
Trial: 29049653
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 10 mg
Trial: 29049653
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 20 mg
Trial: 29049653
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 40 mg (4-week dose escalation)
Trial: 29049653
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide 1.0 mg
Trial: 18447101
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of bupropion, nicotine patch, and individual counseling for 8 weeks
Trial: 16528136
Drug: Ziprasidone (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (40-80 mg b.i.d.)
Trial: 16528136
Drug: Amisulpride (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50-100 mg b.i.d.)
Trial: 11012492
Drug: Peribulbar block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar block with 10 ml of 0.25% bupivacaine
Trial: 11012492
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 150 microg.kg‐1
Trial: 1329742
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g orally b.i.d.)
Trial: 31761958
Drug: Topical rapamycin
RxNorm normalized name: natamycin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rapamycin
Trial: 19377716
Drug: Oral cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cancer screening by visual inspection (3 rounds between 1996 and 2004)
Trial: 19377716
Drug: Oral cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cancer screening by visual inspection
Trial: 17576782
Drug: Thrice-daily hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Thrice-daily hydrocortisone dosing (mean total daily dose: 8.3 +/- 2.6 mg/m2)
Trial: 17576782
Drug: Twice-daily hydrocortisone
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily hydrocortisone dosing (mean total daily dose: 7.6 +/- 2.1 mg/m2)
Trial: 17576782
Drug: Morning doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning doses > 4 mg/m2
Trial: 17576782
Drug: Evening doses
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening doses > 2.5 mg/m2
Trial: 15120772
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied morphine sulfate 10 mg in Intrasite gel
Trial: 15120772
Drug: Subcutaneously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered morphine sulfate 10 mg
Trial: 9513329
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and small dose of fentanyl (Group P)
Trial: 29800584
Drug: Compound unconditioned
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound unconditioned stimulus (UCS) - electric shock combined with a scream noise
Trial: 18246678
Drug: Rehmannia Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehmannia Oral Liquid
Trial: 15170087
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy (IRT) using rhenium-188-filled balloon system
Trial: 11219972
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate followed by i.v. bolus 5-FU
Trial: 26374429
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion 5-FU
Trial: 9640152
Drug: remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1
Trial: 9640152
Drug: remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1 with glycopyrrolate 200 micrograms
Trial: 9640152
Drug: glycopyrrolate 200
RxNorm normalized name: Glycopyrrolate 200 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycopyrrolate 200 micrograms and remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1
Trial: 2645918
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 to 120 mg/d given in divided dosage) for twelve weeks
Trial: 2645918
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 to 120 mg/d given in divided dosage) for four weeks
Trial: 31688091
Drug: Antisense-oligonucleotide therapy
RxNorm normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisense-oligonucleotide therapy
Trial: 31688091
Drug: RNA interference
RxNorm normalized name: Double stranded oligomer ADS-001 RNA interference-based liver targeted therapeutic
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA interference therapy
Trial: 18512816
Drug: Oral bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bovine type I collagen (500 microg/day)
Trial: 15070917
Drug: Flutamide (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (62.5 mg/d) plus Metformin (850 mg/d)
Trial: 15070917
Drug: Ethinylestradiol-drospirenone (OC)
RxNorm normalized name: drospirenone and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol-drospirenone (OC) plus Flutamide-Metformin
Trial: 1679659
Drug: Clobazam 10
RxNorm normalized name: cloBAZam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam 10 mg
Trial: 26087226
Drug: Web-based alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based alcohol treatment program with intensive asynchronous therapeutic support
Trial: 15283001
Drug: L-dopa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (200 mg) plus carbidopa (50 mg) administered at night (11 pm)
Trial: 15283001
Drug: L-dopa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (200 mg) plus carbidopa (50 mg) administered during the day (11 am)
Trial: 8989345
Drug: 750 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/kg RSV‐IGIV
Trial: 8235924
Drug: Cefotaxime 500
RxNorm normalized name: cefotaxime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 500 mg intramuscularly
Trial: 3321412
Drug: Norfloxacin 200
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 200 mg or 400 mg b.i.d. for 7 days
Trial: 11918228
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of cod liver oil with vitamin D (n = 575)
Trial: 11918228
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of cod liver oil without vitamin D (n = 569)
Trial: 26242794
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of depression
Trial: 9439181
Drug: Obesity/diabetes mellitus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obesity/diabetes mellitus treatment
Trial: 8129410
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin (0.025% cream)
Trial: 8129410
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral isotretinoin (10 mg/d)
Trial: 148436
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream
Trial: 2679513
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal gel (1 or 2mg, repeated if necessary at 6 hours)
Trial: 21123762
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of atrial natriuretic peptide (ANP) at 10 ng·kg(‐1)·min(‐1)
Trial: 21123762
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of angiotensin II (ANG II) at 10 ng·kg(‐1)·min(‐1)
Trial: 21123762
Drug: ANG II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANG II with simultaneous infusion of nitroprusside
Trial: 21123762
Drug: Simultaneous intravenous
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous intravenous infusion of ANP (10 ng·kg(‐1)·min(‐1)) with ANG II and nitroprusside
Trial: 19204058
Drug: Postnatal corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postnatal corticosteroids (dexamethasone), total dose tertiles: <0.9, 0.9‐1.9, and >/=1.9 mg/kg
Trial: 15365275
Drug: Lisinopril up-titration
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril up-titration (40 mg for 8 weeks)
Trial: 15365275
Drug: Lisinopril plus
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril plus candesartan (16 mg for 2 weeks followed by 32 mg for 6 weeks)
Trial: 15365275
Drug: Post hoc
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post hoc pooled analysis of lisinopril plus candesartan
Trial: 10321674
Drug: Pentoxifylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (5 mg/kg/hr for 6 hrs on 6 successive days)
Trial: 2018406
Drug: Short recall
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short recall periods (e.g., last weekend, the past 5 days) (Study 3)
Trial: 26679977
Drug: Nasally inhaled
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasally inhaled isopropyl alcohol
Trial: 26679977
Drug: Nasally inhaled
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasally inhaled normal saline solution (placebo)
Trial: 24845609
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg, 3 times daily)
Trial: 28043903
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg daily)
Trial: 22194371
Drug: Posterior vertebral
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior vertebral arch cement augmentation (spinoplasty)
Trial: 19063731
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin therapy (10 ml/kg over 4-6 hours, repeated 48 hours later)
Trial: 11818199
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT 300 mg/m2/day plus oral LV 90 mg/day for 28 days every 5 weeks
Trial: 11818199
Drug: i.v. 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. 5‐FU 425 mg/m2/day plus LV 20 mg/m2/day for 5 days every 4 weeks
Trial: 15842464
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT
Trial: 8820252
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg capsules)
Trial: 19362675
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg intravenous infusion)
Trial: 25510286
Drug: Oral fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fish oil supplementation
Trial: 23623849
Drug: Phenytoin/Valproate (third-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin/Valproate (third-line standard treatment)
Trial: 21823043
Drug: Pioglitazone (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-30 mg/day)
Trial: 21823043
Drug: Metformin (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500-750 mg/day)
Trial: 15720808
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5-FU
Trial: 11401110
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin (EPO) and intravenous (IV) iron
Trial: 9424006
Drug: Hyperfractionated XRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated XRT (total dose 69.60‐76.80 Gy, 1.2 Gy b.i.d. five times a week) combined with superficial external HT (2 to 6 sessions)
Trial: 24921211
Drug: Rabeprazole, Amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole, Amoxicillin, and Metronidazole (RAM)
Trial: 22091740
Drug: Short-acting β‐agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting β‐agonist
Trial: 19071883
Drug: Mipomersen sodium
RxNorm normalized name: Mipomersen Sodium
DrugBank: Mipomersen (DB05528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mipomersen sodium 200 mg
Trial: 12893645
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose house dust mite allergen exposure
Trial: 8268899
Drug: Combined tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined tablet containing hydrochlorothiazide 25 mg and amiloride 2.5 mg
Trial: 29400921
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg once daily for up to 28 days
Trial: 28251654
Drug: BGCC (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGCC (3 g d-1) for 12 weeks
Trial: 19738017
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of n-propanol with CHG
Trial: 16368077
Drug: Dexamethasone/corticotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone/corticotropin-releasing hormone (DEX/CRH) test after 8 weeks of antidepressant treatment
Trial: 6140261
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg and 10 mg)
Trial: 7996118
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (KT) 60 mg to 2 ml
Trial: 31778291
Drug: Stratified exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified exercise therapy (subgroup-specific protocolized exercise therapy, with dietary intervention for obesity subgroup)
Trial: 31778291
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care by physical therapists (nonstratified exercise therapy)
Trial: 28502744
Drug: High-dose sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sodium selenite (4000 μg IV after induction, 1000 μg/d during ICU stay)
Trial: 25142039
Drug: Memantine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (5 to 20 mg/day; n=20)
Trial: 10757577
Drug: Prilocaine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine (80 mg, 20 mg/ml)
Trial: 10757577
Drug: Lidocaine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (80 mg, 20 mg/ml)